Tag: KDC-MN-364

  • Darbepoetin alfa

    Long-acting EPO analog

    A hyperglycosylated EPO analog with two additional N-linked glycan chains; extended plasma half-life for less frequent dosing.

    Abstract

    Darbepoetin alfa (CAS 209810-58-2; modified EPO with two additional N-linked glycosylation sites at amino acid positions 30 and 88; molecular weight approximately 37 kDa) is a hyperglycosylated EPO analog developed at Amgen and approved by the FDA in 2001 (Aranesp). The compound has the same EPO receptor binding mechanism as native EPO but with substantially extended plasma half-life (approximately 25 hours subcutaneous, versus 6 to 13 hours for native EPO) owing to the additional carbohydrate chains slowing renal and hepatic clearance. The receptor binding affinity is approximately 4-fold lower than native EPO at equimolar doses, but the longer half-life produces greater erythropoietic effect per dose. Approved indications match native EPO (CKD anemia, chemotherapy-induced anemia). Used as the canonical long-acting EPO analog in research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.